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The effect of endograft relining on sac expansion
after endovascular aneurysm repair with the
original-permeability Gore Excluder abdominal
aortic aneurysm endoprosthesis
Philip P. Goodney, MD, and Mark F. Fillinger, MD, Lebanon, NH
Objective: Endovascular abdominal aortic aneurysm repair (EVAR) with the original-permeability Excluder (W.L. Gore
& Associates, Flagstaff, Ariz) has been associated with postoperative sac expansion in the absence of endoleak. In these
cases, we have performed an endovascular revision, relining the original endograft with another Excluder, in an effort to
arrest sac expansion by reducing permeability. We have studied these cases to determine the effect of relining on aneurysm
expansion.
Methods: Patients who demonstrated sac expansion (>5 mm diameter, >5% three-dimensional volume) after EVAR with
the original Excluder were evaluated. Between 1999 and 2004, the original-permeability endoprosthesis was used in 97
patients who underwent EVAR for asymptomatic abdominal aortic aneurysm (AAA). Sac expansion occurred in 24
patients, of which multiple imaging modalities showed 12 had expansion without demonstrable endoleak. Nine of the 12
have had endovascular relining, and five of these nine have>6months follow-up to form the primary basis for this report.
Results:AAA size was stable or smaller in the first 6months after the original EVAR for all patients. Once expansion began
(typically in the time frame of 6 to 12 months), multimodality imaging showed no aneurysm spontaneously decreased in
size without intervention, despite the absence of endoleak (n  12). Expansion exceeded clinically significant thresholds
at 30months (mean) by diameter criteria and 22months (mean) by three-dimensional volume criteria for the five patients
with >6 months follow-up after relining. Endovascular relining was performed at a mean of 36 months, with a mean
hospital stay of 1 day, and no morbidity or mortality. Over the entire duration of expansion (mean, 26 months),
aneurysms expanded by 6.0  1 mm/year diameter and by 12%  2%/year by three-dimensional volume. At a mean of
16 months follow-up after relining with another Excluder, the mean diameter decrease was 2.0 mm/year (P < .03) and
the mean volume decrease was 2.6%/year (P< .01). After relining, all AAAs were smaller by diameter or volume, or both,
exceeding thresholds defining shrinkage in two of the five with>6months follow-up after relining. There was no rupture,
migration, endoleak, conversion to open repair, or aneurysm-related death in any patient.
Conclusions: It appears from the initial follow-up that AAA expansion owing to permeability issues after EVAR with the
original Excluder can be arrested by endovascular relining with a low-permeability Excluder endoprosthesis. ( J Vasc
Surg 2007;45:686-93.)The Excluder endoprosthesis (W. L. Gore & Associ-
ates, Flagstaff, Ariz) has a good safety profile for endovas-
cular repair (EVAR) of abdominal aortic aneurysms
(AAA).1-3 Despite this fact, several reports indicate a signif-
icant percentage of enlarging AAAs after repair with what is
now known as the “original” Excluder.4-8 Of interest is that
when AAAs enlarging after EVAR with the original Ex-
cluder are evaluated, most have no endoleak.7,9 Most con-
versions to open repair have also involved expansion with-
out detected endoleak, often referred to as endotension.9
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686Complications related to sac enlargement in the ab-
sence of endoleak appear to be uncommon, but rupture,
loss of proximal seal zone, and conversion to open repair or
other secondary interventions have been reported.1,3,7,9-13
Partly because of the low number of reported complica-
tions, the true nature of endotension and its natural history
are not entirely clear. Examination of fluid withdrawn from
the sac by direct puncture, reports on the sac at the time of
conversion, and explanted devices have all indicated that in
many cases enlargement in the absence of endoleak with the
original Excluder is due to material permeability.1,9,10,14
The problem appears to have been corrected by chang-
ing the graft material in the newer low-permeability Ex-
cluder LP,8 but that does not address the problem of
endotension in patients with the original Excluder. The
problem may be solved by conversion to open repair, but
this carries a significant risk to the patient. Less invasive
options such as laparoscopic sac fenestration and aspiration
of the sac have been performed but have not been success-
ful.15
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sion secondary to graft permeability can be arrested by
relining the original-permeability endoprosthesis with an-
other endoprosthesis. We performed the initial such proce-
dure in 2002, and have performed relining more frequently
recently, encouraged by information on explanted endografts
(Fig 1) and the availability of the low-permeability Excluder
endoprosthesis in 2004. Over time, it has become clear that
the incidence of AAA enlargement without endoleak is
significant. Thus, we have continually updated and re-
viewed all patients at our institution that underwent place-
ment of the original-permeability Excluder endoprosthesis,
experienced sac expansion in the absence of endoleak, and
underwent endovascular relining with Excluder components.
At this pointwebelieve the series has sufficient procedures and
length of follow-up to form this preliminary report.
METHODS
Patients. All patients undergoing endovascular ab-
dominal aortic aneurysm repair at Dartmouth-Hitchcock
Medical Center are prospectively entered into a database,
including serial three-dimensional (3D) imaging and stan-
dard anatomic measurements. All patients who underwent
Fig 1. Explanted Excluder removed because of sac expansion in
the absence of endoleak. Note the proteinaceous material depos-
ited throughout the area where the graft was within the aneurysm
sac. The only place within the sac where material did not accumu-
late on the graft was on the docking limb where it overlaps with the
contralateral limb, creating two thicknesses of graft material. This
reinforced our belief that two thicknesses of graft material might
prevent the transmigration of fluid that appears to be causing sac
expansion in the absence of endoleak.elective EVAR of an AAA using an original-permeabilityExcluder endoprosthesis were included in our initial re-
view. The review was used to determine the number of
AAAs with expansion as defined by Society of Vascular
Surgery (SVS) standards (5mmmaximumAAA diameter
or 5% sac expansion by 3D volume),16,17 the proportion
expanding without endoleak, and the number that under-
went endovascular relining procedures.
Operative technique for primary endovascular
abdominal aortic aneurysm repair. All patients underwent
primary repair of their AAA with the original-permeability Ex-
cluder endoprosthesis according the manufacturer’s in-
structions for use.18 All EVARs were performed in the
operating room with a 12-inch digital C-arm fluoroscopy
unit (GE/OEC 9800, GE Medical Systems, Milwaukee,
Wis; or previously, Philips BV 312, Philips Medical Sys-
tems, Santa Ana, Calif) and carbon-fiber table. Completion
arteriography was always performed, with antegrade con-
trast injection at the proximal attachment site and separate
retrograde injection in both iliac arteries. Other injection
sites (junction injection, separate views) were used as nec-
essary if endoleak was present to rule out type I or type III
endoleak.
Imaging. Preoperative and postoperative imaging was
primarily spiral computed tomography (CT) with 3D re-
construction and Computer AidedMeasurement, Planning
and Simulation (3D CAMPS) software (Preview M2S,
formerly Medical Metrix Solutions, West Lebanon, NH).
Scans covered a volume from the celiac to the common
femoral arteries using a scan protocol with the 3D CAMPS
technique, which has been previously published in de-
tail.19-21 Electronic data from CT angiography (CTA) or
magnetic resonance angiography (MRA) was sent in Digi-
tal Imaging and Communication in Medicine (DICOM)
format for postprocessing by M2S, including multiplanar
reformats encompassing the entire volume of the scan in
sagittal, coronal, and axial planes at 0.75-mm to 2-mm
intervals and orthogonal reformats (perpendicular to the
vessel) at 1-mm intervals.
Measurements were performed using validated tech-
niques, including electronic calipers and standard measure-
ment definitions including SVS Reporting Standards.16,17
Key anatomic parameters included maximum AAA diame-
ter change and 3D volume change measured from the
lowest renal artery to the aortic bifurcation and from the
lowest renal artery to the common iliac artery bifurcation to
capture changes in patients with iliac aneurysms. Diameters
were measured orthogonal to the vessel (ie, in a plane at a
right angle to the centerline of the lumen).
Methods for 3D volume measurements used standard
3D reconstruction techniques described previously,19-22
which were validated on phantoms of known size and
clinically on aortic aneurysms, with interobserver variability
5%. As determined from both interobserver variability
and SVS Reporting Standards, the thresholds used to de-
fine expansion or shrinkage were 5 mm for diameter and
5% for 3D volume.16,21
Spiral CT, 3D reconstruction images, and morphomet-
ric data for all patients were prospectively collected and
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phology over time. These data were used for patient eval-
uation and management purposes as standard of care.
Patient follow-up. All patients were scheduled for
interval follow-up at 1, 6, and 12months, with annual visits
thereafter. Interim visits were scheduled as clinically indi-
cated. Each visit included a patient interview, review of
systems, physical examination, determination of ankle-
brachial index if indicated, and CT scan with 3D recon-
struction including volume measurements. Abdominal ra-
diographs (four views) were performed to evaluate for
fracture or according to clinical trial protocol. Additional
studies, including duplex ultrasonography and angiogra-
phy, were performed as clinically indicated. If relining was
performed, patients were scheduled for interval follow-up
at 1, 6, and 12 months, with annual visits thereafter.
Evaluation before secondary intervention. Any pa-
tient who had experienced significant sac expansion by
volume or diameter criteria was carefully examined for
endoleak. Multimodality imaging methods, including CT,
delayed-contrast CT, delayed-contrast MRA, duplex, and
arteriography, were used for further evaluation of potential
endoleak as deemed appropriate by the surgeon. All pa-
tients had delayed-contrast CTA as the minimum extent of
further evaluation, with a delay of 3 to 5minutes for venous
phase contrast enhancement.20 Angiography was also per-
Fig 2. Relining strategy. Relining was performed in one of three
ways. A, First, if only the limbs were in contact with the sac, only
the limbs were relined, using Excluder limbs delivered via bilateral
12F sheaths. Alternatively, if both limbs and the lower portion of
the main body were in contact with the sac, we relined both the
limbs and the lower portion of the main body, in one of two ways.
B, If the main body was 23 mm in diameter, this was accomplished
with only two limbs by advancing the bifurcation. This is possible
because the diameter of two Excluder limbs, which are 16 mm in
diameter proximally, have essentially the same cross-sectional area
as a 23-mm diameter main body. C, For the larger 26-mm and
28-mm diameter main body Excluder devices, relining required an
aortic cuff to cover the lower portion of themain body, followed by
bilateral limb placement to reline the remainder of the graft. This
requires an 18F sheath on one side and a 12F sheath on the other.formed at the time of relining to confirm the absence ofendoleak in all cases. Patients with expansion and endoleak
of any kind were excluded from analysis in this study. Those
patients with sac expansion in the absence of endoleak had
discussion of the options, including closer follow-up, con-
version to open repair, or a relining procedure.
Secondary interventions. Secondary interventions
described in this study consisted of relining the original-
permeability Excluder endoprosthesis with another set of
Excluder components. The goal of relining in each case was
to cover any portion of the original endograft that was
within the aneurysm sac not in apposition to vessel, as
shown in Fig 2. Preoperative 3D CAMPS was used in a
fashion similar to the original EVAR placement to review
each patient’s images, and a plan was designed to cover the
original-permeability endoprosthesis if no endoleak was
detected at angiography. Relining was performed with
Excluder components in all cases. An original Excluder was
used for the initial case in 2002, and low-permeability
Excluder components were always used after their release in
August 2004. All patients were then followed up postop-
eratively in a manner similar to the first intervention.
Statistical analysis. The size change for each 6-month
interval and for the duration of the expansion and relining
time periods were analyzed with the Statview statistical
software package (SAS Institute, Cary NC). Analysis of
variance or t test were used where appropriate to delineate
quantitative changes over time. Although sac size change in
our overall series and in this cohort appeared consistent
with a normal distribution, we also evaluated the changes
for key differences with nonparametric methods (Wilcoxon
signed rank test), and presented ranges of the data to avoid
any concern about the normality of the data. All P values
shown to be significant by parametric methods were also
significant (P  .05) by nonparametric methods.
RESULTS
Patient population. Between 1999 and 2004, EVAR
was performed electively on 97 patients for asymptomatic
AAA using the original-permeability Excluder endopros-
thesis (a subset of nearly 500 endovascular repairs). Mean
follow-up for these 97 patients was 33 months at the time
of the analysis. Sac expansion has been detected by both
diameter and volume criteria in 24 of 97 patients, and 12 of
these were enlarging with no demonstrable endoleak on
multiple imaging modalities (the other 12 had type II
endoleak during expansion). Four other patients were en-
larging by volume criteria only, none with endoleak.
All patients had evaluation to rule out endoleak as
described in the Methods section. All patients considered
for relining had arterial-phase CTA, delayed-contrast venous-
phase CTA, and angiography as a minimum, and some also
had duplex or MRA, or both.
Of the patients enlarging without apparent endoleak,
nine have undergone relining procedures, and five of these
nine have 6 months’ follow-up after relining to form the
primary basis for this report. The mean follow-up after
relining was 16 months (range, 7 to 24 months). Patient
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longer follow-up are summarized in Table I.
Duration of follow-up and time to clinically signif-
icant expansion. For the five patients with 6 months’
follow-up after relining, expansion began in the 6-month
to 12-month time period in four, and in the 12-month to
24-month time period for the other. The mean time to
exceed the threshold defining sac expansion was 22months
by 3D volume criteria and 30 months by diameter criteria.
The mean duration of follow-up from primary EVAR to
endovascular relining was 36 months (range, 28 to 46
months). Overall AAA enlargement at the time of relining
was a 10.5-mm increase in maximal diameter and 26%
increase in 3D volume relative to the smallest size of the
aneurysm postoperatively. Mean AAA diameter at relining
was 6.3 cm by CT orthogonal cross section (see Methods).
Expansion rates were slower in the patients who were
relined more recently or have not yet been relined (see
“Pattern of sac behavior,” which follows).
The endovascular relining procedure. Various strat-
egies were used for relining (Fig 2). Three of the five
patients with longer follow-up underwent relining of the
limbs of the graft only, with the limbs in standard position.
One additional patient underwent relining with limbs only,
but with the “advancing the bifurcation” technique (Fig 2).
One patient underwent relining with an aortic cuff as well as
iliac limbs. The procedure was performed using open fem-
oral exposure in three patients and percutaneous tech-
niques in two. Contrast was used to confirm the absence of
endoleak, as it was not needed for device placement. Mean
contrast use was 90 mL, fluoroscopy time, 26 minutes, and
estimated blood loss, 190 mL.
All patients went home on postoperative day 1 after
overnight observation. No mortality or morbidity was re-
ported during the hospital stay or at follow-up clinic visits
(range, 7 to 24 months). No rupture, migration, endoleak,
conversion, or other secondary intervention for endograft
Table I. Patient characteristics and demographics for the
five patients with longer follow-up
Patient characteristics
Age (mean years) 74
Male Sex 80%
History of coronary disease 60%
History of renal insufficiency 20%
History of hypertension 100%
History of hyperlipidemia 40%
Anticoagulation
Aspirin 100%
Warfarin 0%
Average time to 5 mm sac expansion by
diameter, months 30
Average time to 5% growth by volume,
months 22
Average duration of follow-up
Before relining, months (range) 36 (28-46)
After relining, months (range) 14 (10-24)or aneurysm problems has occurred in any patient.Four procedures in this series were relatively recent and
so far only have a CT scan at 1month after relining. In three
of these patients, both limbs were relined percutaneously,
and in one patient both limbs and trunk were relined, using
femoral exposure. One patient had concomitant hernia
repair. Two patients each were discharged on postoperative
day 1 or 2.Mean fluoroscopy time was 15minutes, contrast
volume was 40 mL (no longer using postrelining contrast
after confirming no endoleak on pre-relining angiography),
and estimated blood loss, 40 mL. At this early time point,
all of these procedures also appear to have successfully
arrested expansion by diameter and volume.
Pattern of sac behavior. A pattern of sac behavior
was apparent in the patients who underwent relining.
After primary EVAR, all of the patients had at least one
CT scan demonstrating that the preoperative expansion
of the AAA had stopped. Most AAAs initially showed
significant decreases in size, with expansion typically
starting in the 6-month to 12-month postoperative time
period. Once expansion began, it did not stop spontane-
ously in any of these AAAs that were expanding without
endoleak. A typical case is illustrated in Fig 3, demon-
strating changes in aneurysm sac diameter and volume
over time, categorized into “phases” both before and
after relining.
Expansion phase. The pattern shown in Fig 3 is also
Fig 3. Pattern of change in (A) abdominal aortic aneurysm
(AAA) diameter and (B) AAA three-dimensional volume in a
single patient after endovascular aneurysm repair (EVAR).apparent when examining size changes over time for the
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pected, the first five AAAs that were relined had a more
rapid rate of expansion than the four more recent relining
cases (significant by both diameter and volume, Table II).
Thus there was a trend for the latter four relining cases to
have a longer duration of expansion before enlarging suffi-
ciently to merit repair (P  .08), but ultimately, a similar
amount of diameter and volume enlargement before relin-
ing.
Of the patients yet to be relined (including those ex-
panding by volume and not diameter), the four with the
longest duration of expansion are also enlarging at a slower
rate than the initial five relining patients (Table II). These
patients have not been relined because of less total expan-
sion than the others or serious comorbidities (one is elderly
and recently diagnosed with lung cancer).
Once expansion began, it has not stopped spontane-
ously in any of these 13 patients expanding without en-
doleak over a substantial period of time. The rate of expan-
sion has been relatively linear for all patients, although in
many cases the rate of expansion has tended to increase
slightly over time, as shown in Fig 3.
Relining phase. Of the three groups listed in Table
II, the relining phase is characterized well for the five
patients with 6 months follow-up. In this group, over
the entire mean 26-month duration of expansion, aneu-
rysms expanded by 6.0  1 mm/y diameter and by 12%
 2%/y by 3D volume, despite the absence of endoleak
by multiple imaging techniques. At a mean of 16
months’ follow-up after relining with another Excluder,
the mean diameter decrease was 2.0 mm/y and the mean
volume decrease was 2.6%/y (P  .03 and P  .01,
respectively, compared with expansion phase, Table II).
The graphic appearance is similar to Fig 3, with relatively
linear growth followed by shrinking or stabilization of
size, or both.
At the last CT measurement a mean 16 months after
relining, all AAAs were smaller by diameter, volume, or
Table II. Expansion phase and relining phase follow-up d
Group Duration of expa
Follow-up after reline
6 months (5 pts) 26  7 (8 t
6 months (4 pts) 46  5 (35
Not relined, enlarging 6 months (4 pts) 30  5 (19
P .08
CT, Computed tomography; 3D, three-dimensional.
Values shown are mean  standard error (range) for all abdominal aortic an
*Rates of expansion are calculated over the entire duration of time that the
of decrease in size are calculated over the entire duration of follow-up after
†The P value in these two columns compares the rate of size change befo
confidence interval intervals, 1.6 to 14.4 mm/y, range does not include
5.8% to23.4%/y, range does not include zero). By nonparametric (Wilc
trend was the same in all five patients).both after relining, and exceeded SVS thresholds definingshrinkage in two of these five patients. No rupture, migra-
tion, endoleak, conversion, or other secondary intervention
for endograft or aneurysm problems has been reported in
any patient.
DISCUSSION
Multiple studies have suggested that sac expansion in
the absence of endoleak is not uncommon after EVAR,
especially with the original Excluder device.3-5,7,9,12,23,24
This has been attributed to material permeability, leading
to a modification of the Excluder graft fabric to make it
essentially impermeable.8,25 Recent work by our group has
demonstrated that sac behavior after EVARwith this newer
low-permeability Excluder endoprosthesis is significantly
improved compared with the original-permeability Excluder
endoprosthesis, and the low-permeability endografts may
have eliminated this problem.8 The issue of sac expansion
with the original Excluder remains, however, with 15,000
to 30,000 devices distributed worldwide3 and 33% of
treated AAAs enlarging at 4 years.3,5,7 Notably, the original
Excluder device has no greater incidence of endoleak than
other devices,26 but as indicated in our series and others
with the original-permeability Excluder device, expansion
without endoleak is at least as common as expansion with
endoleak.3,7,9
Treatment options for sac expansion after EVAR with-
out apparent endoleak (endotension) are difficult, owing to
the combination of an uncertain natural history for endo-
tension and the treatment options. Before this report, the
only treatment that appeared to be effective for endoten-
sion was conversion to open repair.9 Given the apparently
low complication rate for expansion owing to endotension,
open repair may be difficult to recommend for many
patients from a risk/benefit standpoint.
Less invasive options, such as laparoscopic fenestration
with resection of the aneurysm wall, opening the abdomen
with tight wrapping of the aneurysm wall around the graft,
and repeated punctures with aspiration of fluid, have all
on and aneurysm size rate of change
Before reline or last CT
(mon) Diameter increase (mm) Volume increase (%)
10.5  2 (6 to 15) 26  9 (10 to 57)
) 9.0  1 (7 to 11) 27  3 (20 to 36)
) 4.0  1 (3 to 8) 16  3 (9 to 23)
.02 .48
ms (AAA).
as expanding before reline or before last CT (for those not relined). Rates
g, with duration calculated to the last measured CT.
after relining. Difference in rate of diameter change: 8.0 mm/y (95%
. Difference in rate of volume change: 14.6%/y (95% confidence interval,
igned rank test which uses only ranks), both values of P .04 (meaning theurati
nsion
o 45)
to 58
to 40
eurys
AAA w
relinin
re and
zero)
oxon sbeen attempted, but ultimately were unsuccessful due to
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sac expansion without endoleak after EVAR with the
original-permeability Excluder can be arrested by relining
the endograft with another Excluder endoprosthesis.
It is important to note that our data indicate a pattern
of initial sac shrinkage, then sac expansion, as shown in
Fig 3. The importance of noting this shrinkage-or-stable
phase is to demonstrate that good results at 6 or 12 months
with the original-permeability Excluder do not imply free-
dom from late expansion, even in the absence of endoleak.
The initial shrinkage is typically followed by a later expan-
sion phase, with expansion typically starting between 12
and 36 months by diameter and 6 to 18 months by 3D
volume, as noted in this series and larger series.7,8,27 Once
expansion began, no patient in our series experienced spon-
taneous cessation of expansion over the long periods of
follow-up summarized in Table II.
Fortunately, this sac expansion appears to be arrested
by relining the original permeability device with low-
permeability Excluder endoprosthesis components. None-
theless, the very nature of the original expansion pattern
makes one hesitate to declare the relining procedure a
permanent solution at this point. Whether the initial suc-
cess will persist probably depends on the low-permeability
fabric, which is dramatically different in tests that make the
original material wet out immediately.8
It is encouraging that at a mean follow-up of 16
months (range, 7 to 24 months), none of the patients in
our series have significant AAA expansion by diameter or
volume. Notably, if the expansion rates before relining had
persisted after relining, all five patients with expansion
during 6months of follow-up would already have exceeded
the threshold for clinically significant expansion.
When should relining of an original permeability endo-
prosthesis be considered? First, the AAA should demon-
strate significant and persistent sac expansion on high-
quality imaging studies, with expansion meeting the SVS
definition of expansion on two successive studies 6
Table II. Continued
Before reline
Rate of diameter
expansion* (mm/y)
Rate of 3D volume
expansion* (%/y)
Dur
6.0  1.1 (3 to 10) 12.0  1.6 (7 to 16) 1
2.4  0.3 (2 to 3) 7.5  1.5 (4 to 10)
1.5  0.3 (1 to 3) 6.2  0.5 (5 to 8)
.004 .02months apart.Second, additional investigation for endoleak should
be performed. In a review of the explants for the Gore
Pivotal trials, Kong et al9 found that eight of 16 conversions
to open repair were for expansion without endoleak, but
two of these were found to be missed endoleak (7 of 16
truly had endoleak).9 Thus, at least one study such as
delayed-contrast CT, delayed contrast MR, or angiography
should be performed to evaluate for slow or low-flow
endoleak.20,28-30 Three-dimensional CT volume studies
are the most sensitive and accurate for detecting size
change, but specialized MR techniques appear more sensi-
tive than CT for detecting endoleak.7,20,27,29-32
For persistent expansion in the absence of endoleak by
multiple modalities, endovascular relining should be con-
sidered. Logically, the relining procedure only needs to
involve the components that are exposed to the aneurysm
sac itself, as illustrated in Fig 2. With this strategy, any
portion of the endograft in contact with the sac is relined
using the minimal number of components and the smallest
possible delivery system. We have used this strategy to treat
nine patients, with minimal morbidity and percutaneous
technique in most cases.
Of course, some will argue that nothing needs to be
done about aneurysms undergoing expansion in the ab-
sence of endoleak. Exploration of the aneurysm sac in these
patients usually does not reveal blood, but rather a hygroma
or gelatinous substance.1,9,10,15 Anecdotal reports suggest
rupture in these cases may be managed successfully without
operation in selected patients, although at least one such
rupture may have been associated with fatal bowel obstruc-
tion.10 Certainly, reports of significant complications from
endotension are uncommon at this point. Despite this, at
least one consensus conference of prominent practitioners
in the field suggested that, “An enlarging aneurysm after
EVAR mandates surgical or interventional treatment,” and
a number of open conversions have been performed for this
problem.9,23
We believe sac expansion in the absence of endoleak
After reline
follow-up
on)
Rate of diameter
change (mm/y)*
Rate of 3D volume
change (%/y)*
(7-24) 2.0  1 (6 to 1) 2.6  2 (10 to 1)
(all 1) NA NA
A NA NA
A .03† .01†ation
(m
6  3
1  0
N
Nmerits consideration of intervention. Sac expansion is asso-
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ative exploration, or conversion to open aneurysm repair.
Even if these events are rare, they can cause significant
morbidity. Expansion without endoleak has caused a pro-
gressively decreasing seal zone within the proximal neck at
least once in our series with the original Excluder device,8
and at least once in the 38 patients enlarging at 4 years in
the Excluder Pivotal trial.7 In each case, this problem was
only detected with serial 3D imaging, suggesting that this
problem may be under-reported. Finally, even in the ab-
sence of complications, there is the cost of increased patient
visits, time for patient counseling about the issue, more
frequent imaging, and more extensive imaging.
CONCLUSION
Our method of relining offers a minimally invasive and
seemingly effective option in the surgical management of
sac expansion in the absence of endoleak. Longer-term
follow-up will demonstrate the efficacy of this strategy (or
lack thereof), but if it remains successful in the long term, it
offers the potential benefits of less frequent follow-up and
reduction in the risk of complications such as rupture or
loss of proximal fixation.
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